Subscribe to Newsletter
Subspecialties Cornea / Ocular Surface

Unlocking CXL’s Molecular Mysteries – With Mice

| Farhad Hafezi

Swiss researchers have developed methods for performing corneal crosslinking with riboflavin and corneal biomechanical testing in mice – opening up the world of transgenics and molecular testing.

Business & Profession Other

Higher Myopia Risk in Firstborns

| Michael Schubert

A recent study on risk factors for myopia show it doesn’t always pay to be the eldest child…

Subspecialties Neuro-ophthalmology

Animation for Amblyopia

| Michael Schubert

Dichoptic films could offer a new and engaging treatment method for children with amblyopia

Subspecialties Retina

Another Vaccine Myth Debunked?

| Roisin McGuigan

Vaccination complications as an explanation for retinal hemorrhage in children should not be accepted clinically or legally, new study data suggests

Subspecialties Refractive

One IOL Formula… To Rule Them All

| Michael Schubert

IOL power calculation formulae all have their own strengths and weaknesses – so researchers decided to combine those strengths into a single “super formula”

Subspecialties Neuro-ophthalmology

All The Better to See You With

| Roisin McGuigan

Using a mouse model to shed new light on a genetic cause of enlarged eyeballs

Subspecialties Retina

AMD Eyedrop Hope

| Roisin McGuigan

Vasotide, a small molecule that stops VEGF binding to endothelial receptor molecules, has shown promise in animal models and can be delivered using eyedrops

Business & Profession Other

The Innovation Game

| Mark Hillen

In eye care, anyone with an idea can make a difference

Subspecialties Retina

U.K. Ophthalmologists Lead in the Treatment of Wet AMD Patients with Oraya Therapy Across Europe

U.K. Ophthalmologists are the leading adopters of Oraya Therapy for the treatment of wet age-related macular degeneration (AMD), two years after the treatment was introduced in the country.

Subspecialties Retina

Oraya Therapy Treatment Video-Full version with treatment animation

Anti-VEGF monotherapy may not be adequate for all your wet AMD patients. The Oraya Therapy™ Stereotactic Radiotherapy for Wet AMD, intended as a one-time treatment, has been shown to maintain vision while reducing the number of anti-VEGF injections, providing a viable option for patients with significant fluid in the macula.

Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: